ArriVent shares plunge after phase 3 failure of China-licensed cancer drug
1 outlet · 0L · 1C · 0R
First reported
1 / 1
We're still gathering coverage of this story.
A neutral account and the side-by-side comparison are written once at least 2 outlets have reported it. Here is the coverage so far.
Left0 articles
No coverage yet.
Centre1 article
Right0 articles
No coverage yet.
- 7 Oct 05:20 First South China Morning PostN US firm ArriVent’s plunge shows risks facing China’s biotech expansion into global markets
Times are when each article was published, or when we first saw it if the outlet gave no time.